SI-BONE Inc. (SIBN) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SIBN scores 53 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The fundamental cash engine pillar scores 9 of 20 (ROIC -10.3%; FCF yield -0.9%), indicating that the business is not currently generating returns on invested capital or free cash flow in excess of its cost, which is the weakest part of the profile and the main reason the composite is low. The whale 13F flow pillar scores 17 of 20 (institutional accumulation and options positioning), the strongest pillar, suggesting institutional participation is a supportive factor even though underlying economics are weak. The insider conviction pillar scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), the lowest score in the rating, and per the news wire a Form 4-related insider sale was reported. The macro regime fit pillar scores 10 of 20 (beta 1.0; sector sensitivity), indicating market-level volatility exposure in line with the broad market. The forensic balance sheet pillar scores 14 of 20 (Altman Z 8.73; Piotroski F 6/9; Debt/Equity 0.2), which is a comparative strength: per the rating, leverage is low and the balance-sheet health indicators are favorable.

For a prospective investor, the upside drivers are the balance-sheet strength and the institutional flow signal, with the stock trading near the upper portion of its 52-week range. The valuation tradeoff is significant: because the P/E, EPS, and EV/EBITDA are not available in source data, the price cannot be tested against earnings, and negative operating and net margins mean the current price rests on expectations rather than demonstrated profitability. The rating's Sell designation reflects that these expectations are not yet supported by the cash engine. Second-order risk lies in the insider pillar: weak insider conviction combined with negative FCF implies that management-level signals do not reinforce the institutional story. This is an analytical framing, not personalized advice.

Per the company profile, SI-BONE Inc. is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the profile, the company has a market capitalization of $1.0B. The source data does not describe its products, customers, or revenue model beyond the sector and industry classification and the reported revenue figures in the SEC financials.

Per the SEC financials, revenue grew from $138.9M in FY 2023 to $200.9M in FY 2025 while operating and net losses narrowed in each year shown. Per the market data, gross margin is 79.6%, operating margin is -11.1%, and net margin is -9.4%, with ROIC at -10.3%. Per the Roarable RQD rating, the Altman Z-Score is 8.73 and the Piotroski F-Score is 6 of 9, with a Debt/Equity ratio of 0.2. Per the SEC financials, FY 2025 cash of $42.2M exceeded debt of $35.6M, while free cash flow remained negative in each reported year.

Per the news wire, five items are listed, all tagged with a YELLOW signal and MARKET WIRE impact label. The items include a general market-data and forecast summary, a report that SIBN shares recently moved, an item describing a tax-withholding sale of 3,133 shares by the legal chief, an item describing a sale of $94,078 in stock by the chief operating and financial officer, and an item discussing a packaging seal recall and its effect on investors. Per the news wire, these are the primary catalysts; the packaging seal recall is a potential operational risk watch item, and the insider sales are relevant to the insider conviction pillar. Per the Butterfly Supply-Chain Graph, the supply-chain field is NONE, with no butterfly links and no proprietary signals.

• What are the company's products, customers, and revenue model, given that the source data provides only sector classification?
• Why are P/E, forward P/E, EV/EBITDA, and EPS unavailable, and what would earnings-based valuation show?
• What is the scope and financial impact of the packaging seal recall referenced in the news wire?
• What is the size and timing of the insider sales relative to the reported holdings and the FY 2025 cash position?
• What drove the change in cash and debt for FY 2023, which is not reported in the source data?